Date Log
case report a rare case of aldosteron-secreting giant adrenal carsinoma: a case report and review of literature
Corresponding Author(s) : Mehtap Evran
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 3 No. 2 (2015): 2015 Volume 3- Issue -2
Abstract
?NTRODUCT?ON
Primary aldosteronism is the most common and curable form of secondary hypertension with on estimated prevalence of 10% in referred patients, and 4% in primary care. Primary aldosteronism is presented with signs of hypertension and hypokalemia classically.
CASE PRESENTAT?ON
A 46 years old male patient was referred to our hospital with weakness, dry mouth and weight loss. He was hypertensive at out-of-office measures as grade II according to last guidelines. The patient was hospitalized to service as primer hiperaldosteronism however adrenocortical carcinoma with distant metastases was detected.
CONCLUS?ON
We presented a case of a man who had isolated aldosterone-producing adrenal cortical carcinoma. This is very rare case and also clinicians should be aware that primary hyperaldosteronism can occur in the context of adrenocortical carcinoma
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
-
[1] Zennaro MC, Boulkroun S, Fernandes-Rosa FL. An update on novel mechanisms of primary aldosteronizm. Journal of Endocr?nology, 2014; 224(2): 63-77.
[2] Conn JW. Aldosterone in clinical medicine; post, present, and future. AMA Arch Intern Med, 1956; 97: 135.
[3] Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol, 2006; 2: 198.
[4] Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf), 2007; 66: 607-18.
[5] Conn JW. Presidental address. Part I: Painting background. Part II: Primary Aldosteronism, a new clinical syndrome. J Lab Clin Med, 1955; 45: 3-17.
[6] Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab, 2010; 95: 4812–22.
[7] Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol, 2011; 60: 1055–1065.
[8] Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol, 2011; 7: 323–35.
[9] Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Uro, 2003;169: 5–11.
[10] Roman S. Adrenocortical carcinoma. Curr Opin Oncol, 2006; 18: 36–42.
[11] Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2008; 93: 3266-81.
[12] Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism. Aust N Z J Med, 1976; 6: 131-5.
[13] Schwartz GL, Turner ST. Screning for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem, 2005; 51: 386-94.
[14] Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two majör subtypes. Arch Intern Med, 1993; 153: 2125-9.
[15] Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery, 2004; 136: 1227-35.
[16] Allolio B, Fassnacht M. Clinical Review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab, 2006; 91: 2027.
[17] Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer, 2000; 88: 711.
[18] Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab, 2013; 98: 4551–64.
[19] Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med, 2012; 366: 2189–97.
[20] Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab, 2013; 98: 192–7.
[21] Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med, 2007; 356: 2372–80.
[22] Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer, 2005; 12: 149–159.
References
[2] Conn JW. Aldosterone in clinical medicine; post, present, and future. AMA Arch Intern Med, 1956; 97: 135.
[3] Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol, 2006; 2: 198.
[4] Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf), 2007; 66: 607-18.
[5] Conn JW. Presidental address. Part I: Painting background. Part II: Primary Aldosteronism, a new clinical syndrome. J Lab Clin Med, 1955; 45: 3-17.
[6] Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab, 2010; 95: 4812–22.
[7] Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol, 2011; 60: 1055–1065.
[8] Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol, 2011; 7: 323–35.
[9] Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Uro, 2003;169: 5–11.
[10] Roman S. Adrenocortical carcinoma. Curr Opin Oncol, 2006; 18: 36–42.
[11] Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2008; 93: 3266-81.
[12] Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism. Aust N Z J Med, 1976; 6: 131-5.
[13] Schwartz GL, Turner ST. Screning for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem, 2005; 51: 386-94.
[14] Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two majör subtypes. Arch Intern Med, 1993; 153: 2125-9.
[15] Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery, 2004; 136: 1227-35.
[16] Allolio B, Fassnacht M. Clinical Review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab, 2006; 91: 2027.
[17] Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer, 2000; 88: 711.
[18] Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab, 2013; 98: 4551–64.
[19] Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med, 2012; 366: 2189–97.
[20] Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab, 2013; 98: 192–7.
[21] Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med, 2007; 356: 2372–80.
[22] Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer, 2005; 12: 149–159.